Early season co-circulation of influenza a(H3N2) and b(yamagata): Interim estimates of 2017/18 vaccine effectiveness, Canada, january 2018

Eurosurveillance

Volumn 23, Issue 5, 2018, Pages

  Skowronski, Danuta M ^a,b   Chambers, Catharine ^a   De Serres, Gaston ^c,d,e   Dickinson, James A ^f   Winter, Anne Luise ^g   Hickman, Rebecca ^a   Chan, Tracy ^a   Jassem, Agatha N ^a,b   Drews, Steven J ^h,i   Charest, Hugues ^c   Gubbay, Jonathan B ^g,j   Bastien, Nathalie ^k   Li, Yan ^k   Krajden, Mel ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g PUBLIC HEALTH ONTARIO   (Canada)

^h Prov Laboratory of Northern Alberta   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k PUBLIC HEALTH AGENCY OF CANADA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VACCINE;

ADULT; ARTICLE; CANADA; CLADISTICS; CONTROLLED STUDY; DRUG EFFICACY; EPIDEMIC; HUMAN; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA B VIRUS; MAJOR CLINICAL STUDY; MALE; SEASONAL VARIATION; ADOLESCENT; CASE CONTROL STUDY; CHILD; CLASSIFICATION; FEMALE; GENETICS; IMMUNOLOGY; INFLUENZA; MIDDLE AGED; SEASON; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CANADA; CASE-CONTROL STUDIES; CHILD; EPIDEMICS; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEASONS; SENTINEL SURVEILLANCE; VACCINATION; VACCINE POTENCY; YOUNG ADULT;

EID: 85041952607     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2018.23.5.18-00035     Document Type: Article

References (22)

1. Public Health Agency of Canada (PHAC). FluWatch: Influenza weekly reports 2017-18 season. Ottawa: PHAC; 2018. [Accessed 15 January 2018]. Available from: https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-reports-2017-2018-season.html.
2. European Centre for Disease Prevention and Control (ECDC). Flu New Europe: Joint ECDC-WHO/Europe weekly influenza update. [Accessed 15 January 2018]. Stockholm: ECDC; 2018. Available from: http://flunewseurope.org/.
3. Centers for Disease Control and Prevention (CDC). FluView: Weekly U.S. influenza surveillance report. Atlanta: CDC; 2018. [Accessed 15 January 2018]. Available from: https://www.cdc.gov/flu/weekly/.
4. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/en/
5. Sullivan SG, Chilver MB, Carville KS, Deng YM, Grant KA, Higgins G, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill. 2017;22(43):pii=17-00707
6. Chambers C, Skowronski DM, Sabaiduc S, Winter AL, Dickinson JA, De Serres G, et al. Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill. 2016;21(11):30168. https://doi. org/10.2807/1560-7917.ES.2016.21.11.30168 PMID: 27020673
7. Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, et al. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014. Euro Surveill. 2014;19(5):20690. https://doi.org/10.2807/1560-7917.ES2014.19.5.20690 PMID: 24524234
8. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):21022. https://doi.org/10.2807/1560-7917.ES2015.20.4.21022 PMID: 25655053
9. Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Euro Surveill. 2017;22(6):30460. https://doi. org/10.2807/1560-7917.ES.2017.22.6.30460 PMID: 28205503
10. Neher RA, Bedford T. nextflu: real-time tracking of seasonal influenza virus evolution in humans. Bioinformatics. 2015;31(21):3546-8.. Available from: http://nextflu.org/h3n2/3y/https://doi.org/10.1093/bioinformatics/btv381 PMID: 26115986
11. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization, summary Europe, December 2017. Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/en/publications-data/influenza-virus-characterisation-summary-europe-december-2017
12. Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, et al. Interim estimates of 2016-17 seasonal influenza vaccine effectiveness - United States, February 2017. MMWR Morb Mortal Wkly Rep. 2017;66(6):167-71. https://doi.org/10.15585/mmwr.mm6606a3 PMID: 28207689
13. Kissling E, Rondy MI-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7):30464. https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464 PMID: 28230524
14. British Columbia Centre for Disease Control (BCCDC). Canadian Sentinel Practitioner Surveillance Network (SPSN) vaccine effectiveness (VE) estimates (95%CI), 2004-05 to 2016-17 seasons. Vancouver: BCCDC. [Accessed: 15 Jan 2018]. Available from: http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Influenza%20and%20Respiratory/SPSN_VE_By_Year_ Table_2017-12-01.pdf
15. Ferdinands J. Influenza vaccine effectiveness 2016-17. Advisory Committee on Immunization Practices (ACIP) meeting, Atlanta, 21-22 June 2017. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-06/flu-03-ferdinands.pdf
16. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm M,, et al. Variable influenza vaccine effectiveness by subtype: a meta-analysis of test negative design studies. Lancet Infect Dis. 2016;16:942-51. https://doi.org/10.1016/S1473-3099(16)00129-8 PMID: 27061888
17. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153. https://doi.org/10.1371/journal. pone.0092153 PMID: 24667168
18. Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci USA. 2017;114(47):12578-83. https://doi.org/10.1073/pnas.1712377114 PMID: 29109276
19. Dugan VG, Blanton L, Elal AIA, Alabi N, Barnes J, Brammer L, et al. Update: influenza activity - United States, October 1-November 25, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(48):1318-26. https://doi.org/10.15585/mmwr. mm6648a2PMID: 29216030
20. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):153. https://doi.org/10.1186/1741-7015-11-153 PMID: 23800265
21. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015-16 season in Canada. J Infect Dis. 2017;216(12):1487-500. https://doi.org/10.1093/infdis/jix526 PMID: 29029166
22. Allen UD, Aoki FY, Evans GA, Laverdiere M, Skowronski DM, Stiver HG. Guidance on use of antiviral drugs given potential low vaccine effectiveness for the 2017-18 season. Ottawa: Association of Medical Microbiology and Infectious Disease Canada. [Accessed: 15 Jan 2018]. Available from: https://www.ammi.ca/Update/79.ENG.pdf